Financial Performance - The company achieved a revenue of RMB 862.5 million for the year ending December 31, 2025, representing a year-on-year growth of 31.3% compared to RMB 657.0 million in 2024[3]. - Adjusted net profit for the year was RMB 33.8 million, a significant turnaround from a loss of RMB 184.1 million in 2024[4]. - The company reported a net profit of RMB 30,241,000 for the year, a turnaround from a net loss of RMB 190,053,000 in 2024[63]. - The gross profit increased to RMB 229.6 million, with a gross margin of 26.6%, up from 16.5% in the previous year[3]. - The gross profit for the year ended December 31, 2025, was RMB 229.6 million, representing a 111.6% increase from RMB 108.5 million in the previous year[22]. - The company reported a pre-tax profit of RMB 31,226,000 for 2025, a significant recovery from a loss of RMB 189,144,000 in 2024[88]. - The company received government subsidies amounting to RMB 30,207,000 in 2025, up from RMB 14,086,000 in 2024, representing a 114.5% increase[84]. Revenue Breakdown - Revenue from mainland China reached RMB 773.8 million, growing by 25.2% year-on-year, while revenue from other countries/regions surged by 127.8% to RMB 88.8 million[19]. - Revenue from copyright broadcasting rights licensing was RMB 773,215,000 in 2025, up from RMB 591,458,000 in 2024, representing a 30.7% growth[76]. - Customer contract revenue for 2025 reached RMB 862,505,000, a 31.1% increase from RMB 657,008,000 in 2024[76]. - Two customers contributed over 10% of total revenue, generating approximately RMB 591,790,000, which accounted for 32% and 37% of total revenue for the year[75]. Content Production - The company produced approximately 200 episodes across six new projects in 2025, enhancing its content production capabilities[6]. - The short-form content segment saw a rapid increase, with 141 short dramas produced, totaling around 10,000 minutes, a nearly 70% increase year-on-year[14]. - The short drama "Northeast Love Story: Flash Marriage Rose" achieved over 2 billion views, becoming a phenomenon in the market[14]. - The company expanded its commercial strategies in the short drama segment, generating approximately RMB 130 million in revenue, a year-on-year increase of about 110%[14]. - The company plans to produce over 200 long dramas in 2026, continuing its focus on high-quality content and international expansion[17]. Financial Position - The company's total assets decreased to RMB 2,569,818,000 from RMB 2,699,017,000 in 2024, reflecting a reduction in non-current assets[64][65]. - Current liabilities increased to RMB 611,689,000 from RMB 518,836,000 in 2024, indicating a rise in short-term financial obligations[64]. - The company’s cash and cash equivalents decreased to RMB 782,800,000 from RMB 1,086,280,000 in 2024, showing a decline in liquidity[64]. - Non-current liabilities decreased significantly to RMB 221,099,000 from RMB 385,167,000, indicating improved long-term financial health[65]. - The company’s equity increased slightly to RMB 2,348,719,000 from RMB 2,313,850,000, reflecting a stable financial position[65]. Receivables and Payables - Trade receivables decreased by 50.0% to RMB 141.3 million as of December 31, 2025, from RMB 282.4 million as of December 31, 2024, due to the collection of accounts receivable from previous years' broadcasts[32]. - Trade payables decreased by 48.9% to RMB 30.5 million as of December 31, 2025, from RMB 59.7 million as of December 31, 2024, primarily due to payments made for prior period amounts[33]. - The aging analysis of trade receivables shows that overdue amounts over one year decreased to RMB 7,134,000 in 2025 from RMB 51,291,000 in 2024, indicating improved payment behavior from customers[93]. - The impairment loss provision for trade receivables decreased significantly from RMB 28,868,000 in 2024 to RMB 717,000 in 2025, indicating better credit quality[94]. Corporate Governance - The company has established an audit committee to oversee financial reporting processes, internal controls, and risk management systems[60]. - The company is committed to maintaining high standards of corporate governance to protect shareholder interests and enhance corporate value[53]. - The company will hold its annual general meeting on May 27, 2026, with a suspension of share transfer registration from May 21 to May 27, 2026[51]. Shareholder Actions - No final dividend is recommended for the year ending December 31, 2025[50]. - The company repurchased a total of 63,400 shares during the reporting period at a total cost of HKD 236,938, reflecting confidence in its business development prospects[58]. - The highest and lowest repurchase prices per share were HKD 3.8 and HKD 3.6, respectively, during December 2025[59].

Financial Performance - Total revenue increased by 135.3% from RMB 1,009.4 million in 2024 to RMB 2,374.9 million in 2025, driven by strong drug sales and licensing income from partnerships [3]. - Drug revenue rose by 43.4% from RMB 1,005.6 million in 2024 to RMB 1,442.4 million in 2025, attributed to the continued growth of Orelabrutinib and the launch of Tanshinone Monoclonal Antibody in Q4 2025 [3]. - Total operating expenses increased by 22.4% from RMB 1,417.8 million in 2024 to RMB 1,735.1 million in 2025, primarily due to higher sales and distribution expenses related to the commercialization of Tanshinone Monoclonal Antibody [4]. - The company achieved a profit of RMB 644.2 million in 2025, a turnaround from a loss of RMB 452.9 million in 2024, marking its first profitable year [5]. - Cash and cash equivalents as of December 31, 2025, were approximately RMB 7.8 billion, providing flexibility for clinical development and investment in competitive product lines [5]. - Gross profit increased by 150.7% from RMB 871.0 million in 2024 to RMB 2,183.8 million in 2025, with a gross margin of 92.0%, up 5.7 percentage points from 86.3% in 2024 [186]. - Other income increased from RMB 210.8 million in 2024 to RMB 262.2 million in 2025, primarily due to government subsidies and foreign exchange gains [188]. Research and Development - Research and development expenses increased by 16.9% from RMB 814.0 million in 2024 to RMB 951.6 million in 2025, reflecting increased investment in technology platform innovation and clinical trials [4]. - The company maintained strong momentum in R&D, achieving multiple regulatory approvals and significant advancements in late-stage clinical trials [8]. - The operational model demonstrated scalability, highlighting improved profitability quality and the ability to convert scientific innovation into sustainable growth [8]. - The company is advancing its late-stage registration projects and next-generation innovative assets targeting B-cell and T-cell mediated diseases, with a focus on developing first-in-class and best-in-class oral therapies [21]. - The company is focusing on developing first-in-class and best-in-class oral therapies for autoimmune diseases, with a product pipeline that includes late-stage registration projects and next-generation assets [92]. Product Development and Approvals - The company achieved significant progress in establishing leadership in the hematologic oncology field, with the commercialization of three cornerstone therapies: Acalabrutinib (BTK inhibitor), Tazemetostat (anti-CD19 monoclonal antibody), and Mesutoclax (BCL-2 inhibitor) by 2025 [9]. - Acalabrutinib was approved for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (1L CLL/SLL) and included in the updated National Reimbursement Drug List (NRDL), contributing to stable annual treatment costs and supporting high-quality revenue growth [9]. - Tazemetostat received regulatory approval in May 2025, with the first prescriptions issued in September 2025, laying a solid foundation for commercialization starting in 2026 [10]. - The company’s core product, Acalabrutinib, showed strong revenue growth, driven by four approved indications included in the NRDL, ensuring stable annual treatment costs [12]. - Mesutoclax is undergoing five clinical trials, including three pivotal registration trials, highlighting its potential as a next-generation BCL-2 inhibitor [17]. - The company is advancing global clinical development of Mesutoclax for treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in multiple regions, including China and the US [17]. - The IND for ICP-538 was approved in February 2026, with recruitment of healthy volunteers starting in March 2026, marking a key milestone for the project [30]. - The IND for ICP-B794 was approved in July 2025, currently in the dose escalation phase, showing good pharmacokinetics and tolerability with initial data indicating disease stabilization in early dose groups [38]. Market Strategy and Collaborations - The company made significant progress in its international strategy through global licensing and collaboration arrangements, enhancing its market presence [8]. - The collaboration with Zenas BioPharma includes a $100 million upfront payment and potential milestone payments exceeding $2 billion, along with tiered royalties based on annual net sales [23]. - A strategic licensing agreement with Zenas BioPharma was established for the development and commercialization of obinutuzumab for multiple sclerosis and other indications outside Greater China and Southeast Asia [42]. - The company has expanded its pipeline through two significant business development transactions, enhancing its international presence and value realization pathways [41]. Clinical Trials and Efficacy - In a Phase I/II study involving 81 patients, mesutoclax (ICP-248) demonstrated an overall response rate (ORR) of 100% in relapsed/refractory CLL/SLL and 87.5% in relapsed/refractory MCL, highlighting its potential in unmet medical needs [19]. - For initial AML patients, 85.7% achieved complete clinical response (cCR) with a 3-month duration of response (DoR) rate of 91.7% and a 6-month overall survival (OS) rate of 94.1% [19]. - The Phase III study for 75 mg QD of obinutuzumab in immune thrombocytopenic purpura (ITP) has completed patient recruitment, with a new drug application expected in Q2 2026 [22]. - In a Phase IIb study for systemic lupus erythematosus (SLE), the 75 mg QD group achieved a SRI-4 response rate of 57.1%, significantly higher than the placebo rate of 34.4% [22]. - The IIb trial results indicated a statistically significant improvement in the efficacy of the drug for SLE patients, with a primary endpoint achieved [104]. Production and Operational Capacity - The Guangzhou production facility has an annual production capacity of one billion tablets and has received production licenses for Orelabrutinib since August 2022 [178]. - The company has established a technology platform at the Guangzhou facility to address challenges in solubility of poorly soluble drugs, enhancing drug bioavailability [178]. - The company has expanded its production area by 21,541 square meters to support the growth of Orelabrutinib and upcoming product launches [179]. Environmental and Social Responsibility - The company has committed to reducing greenhouse gas emissions intensity, energy usage intensity, and industrial wastewater discharge intensity by 10% from 2023 levels by 2028 [181].

Financial Performance - For the year ended December 31, 2025, the total revenue of the company reached approximately RMB 716.5 million, an increase of about 20.7% compared to RMB 593.4 million for the year ended December 31, 2024[5]. - The gross profit for the year ended December 31, 2025, was approximately RMB 108.9 million, representing a 23.0% increase from RMB 88.6 million in the previous year, with a gross margin of 15.2%, up 0.3 percentage points from 14.9%[5]. - The company reported a net loss of approximately RMB 163.8 million for the year ended December 31, 2025, a reduction of about 30.5% from a net loss of RMB 235.9 million in 2024[5]. - The company's revenue increased by approximately 20.7% from RMB 593.4 million in 2024 to RMB 716.5 million in 2025, primarily driven by the expansion of its business scale[21]. - The net loss for the year decreased by approximately 30.5% from RMB 235.9 million in 2024 to RMB 163.8 million in 2025[32]. - The company reported a revenue of RMB 716.5 million for the year ended December 31, 2025, an increase of 20.8% from RMB 593.4 million in 2024[65]. - The net loss for the year was RMB 163.8 million, compared to a net loss of RMB 235.9 million in the previous year, reflecting a reduction of 30.6%[65]. Sales and Market Expansion - The company delivered approximately 619.5 thousand electric vehicle charging piles in 2025, a growth of about 76.4% compared to 351.1 thousand in 2024, with domestic sales to automakers increasing by 68.8%[7]. - Overseas business revenue exceeded RMB 100 million for the first time, accounting for approximately 17.1% of total revenue, up from 12.1% in 2024, with a year-on-year growth of about 70.5%[7]. - The company has positioned itself as a trusted partner for leading automakers in China, providing charging piles and services to nine of the top ten automakers by sales volume in 2025[10]. - The company has launched its own retail brand "Zhida," which has rapidly accumulated a large user base and is recognized as one of the top three brands in the retail sales of electric vehicle charging piles on e-commerce platforms[12]. - The company plans to accelerate global expansion, particularly in high-profit markets like Europe and emerging markets in Southeast Asia, South America, and the Middle East[16]. - The company aims to enhance retail sales channels to reduce reliance on manufacturer-led sales, targeting higher profit margin opportunities[16]. Cost Management and Efficiency - The company's administrative and R&D expenses decreased by approximately 3.6% from RMB 159.5 million in 2024 to RMB 153.8 million in 2025 due to cost control measures[26]. - Financial asset impairment losses decreased by approximately 79.2% from RMB 38.5 million in 2024 to RMB 8.0 million in 2025, mainly due to a reduction in individual credit impairment losses[27]. - Operating loss decreased to RMB 146.9 million in 2025 from RMB 218.9 million in 2024, indicating an improvement in operational efficiency[65]. Assets and Liabilities - Total assets increased to RMB 1,124,168,000 in 2025, up from RMB 836,438,000 in 2024, reflecting a growth of about 34.4%[68]. - Trade receivables and notes increased by approximately 41.1% from RMB 306.4 million on December 31, 2024, to RMB 432.3 million on December 31, 2025, primarily due to increased sales[34]. - Cash and cash equivalents increased by approximately 106.3% from RMB 141.4 million on December 31, 2024, to RMB 291.6 million on December 31, 2025, primarily due to net proceeds from a global offering[37]. - The company's total liabilities amounted to RMB 880,048,000 in 2025, compared to RMB 787,286,000 in 2024, which is an increase of approximately 11.8%[69]. - The equity attributable to the owners of the company rose to RMB 240,826,000 in 2025, compared to RMB 45,860,000 in 2024, reflecting a significant increase of about 424.5%[68]. Research and Development - The company has developed advanced products with higher gross margins, including electric vehicle charging robots and EMS solutions, which are key to digital home energy management[13]. - Research and development is allocated 36.5% of the net proceeds, with RMB 119.2 million planned, and only RMB 13.8 million utilized so far[57]. - The company’s research and development expenses for the year included a tax deduction of RMB 6,195,000, compared to RMB 5,087,000 in 2024[102]. Other Financial Information - The other income, primarily from government subsidies, increased by approximately 66.5% from RMB 6.1 million in 2024 to RMB 10.1 million in 2025[25]. - The group’s total expenses for the year ended December 31, 2025, were RMB 862,615,000, an increase of 10.7% from RMB 779,001,000 in 2024[92]. - The group recognized government grants of RMB 10,136,000 in 2025, up from RMB 6,089,000 in 2024, a growth of 66.7%[90]. - The company has no significant contingent liabilities as of December 31, 2025, compared to zero on December 31, 2024[43]. - The company did not declare or pay any dividends for the year ended December 31, 2025, consistent with 2024[106]. Audit and Compliance - The auditor, PwC, confirmed that the amounts in the preliminary announcement align with the consolidated financial statements for the year ending December 31, 2025[119]. - The audit committee consists of three members: Ms. Wu Yushan, Ms. Sun Zhili, and Dr. Lu Ming, with Ms. Wu serving as the chairperson[118].

Financial Performance - For the fiscal year ending December 31, 2025, the company reported a revenue of RMB 1,064.5 million, representing an 11.1% year-over-year increase[3]. - Gross profit reached RMB 267.0 million, up 18.2% from the previous year, with a gross margin improvement from 23.6% to 25.1%[3]. - Net profit surged to RMB 131.4 million, reflecting a significant increase of 63.8% compared to the prior year[3]. - Adjusted net profit (non-IFRS) was RMB 25.6 million, a remarkable increase of 139.7% year-over-year[3]. - The company achieved an adjusted operating profit of RMB 40.2 million, marking a 224.1% increase from the previous year[3]. - The adjusted EBITDA was RMB 173.1 million, which is a 16.8% increase compared to the previous year[3]. - The company's revenue increased by 11.1% from RMB 958.6 million in 2024 to RMB 1,064.5 million in 2025, driven by growth in physical medical services[41]. - Revenue from physical medical services rose to RMB 980.4 million, accounting for 92.1% of total revenue in 2025, compared to RMB 872.4 million and 91.1% in 2024[42]. - The net profit for 2025 is RMB 131,449,000, compared to RMB 80,227,000 in 2024, representing an increase of 64%[87]. - Total comprehensive income for 2025 is RMB 158,372,000, a significant recovery from a loss of RMB 14,943,000 in 2024[87]. Member Growth and Engagement - The number of member accounts and new member acquisitions showed steady growth, with a net promoter score (NPS) increasing from 86.2 to 87.3, indicating strong customer loyalty[6]. - As of December 31, 2025, the number of effective members reached 117,551 households, contributing 73.6% of total revenue[22]. - The new member count for 2025 was 36,286 households, with a new member conversion rate of 79.7%[22]. - The member renewal rate increased to 67.9% in 2025, up from 65.2% in 2024, reflecting growing member trust in services[21]. - The average annual spending per active member household increased from RMB 3,016 in 2023 to RMB 5,866 in 2025, indicating enhanced member engagement[23]. - The average annual spending of new member households in 2025 was RMB 3,813, showing a steady increase in member value[24]. Service Expansion and Operations - The company operated 18 multi-specialty service points in China as of December 31, 2025, focusing on upgrading to one-stop health service centers[8]. - The company plans to accelerate the expansion of one-stop health service centers, with a focus on upgrading locations in Suzhou, Changsha, Shenzhen, Wuhan, and Beijing by 2026[34]. - A new health subscription service combining innovative drugs and medical services is set to launch, targeting weight loss, sleep, and allergies, with plans to expand into other areas by 2026[35]. - The company is developing a personalized AI health assistant to create comprehensive health profiles for families, integrating health data and providing proactive intervention suggestions[36]. - The company plans to expand its integrated medical services by increasing the total building area from 5,754 square meters to 6,855 square meters by August 2026[41]. Technology and Innovation - AI-assisted appointment processing achieved a coverage rate of 77% and reduced processing time from 5 minutes to 1.5 minutes, improving user experience[26]. - AI-driven customer relationship management (CRM) tasks saw an 84% automation rate, with follow-up consultation rates increasing from 46% to 52%[27]. - The company implemented AI in post-consultation follow-ups, providing services to nearly 10,000 users monthly, enhancing user loyalty[26]. - The company will implement a new generation of self-developed EMR systems by 2026, integrating AI capabilities to enhance healthcare service quality and operational efficiency[37]. - A collaboration with a university has led to the design and development of a multi-agent architecture, currently in testing, aimed at improving AI response accuracy and handling complex queries[37]. Financial Management - Administrative expenses decreased by 17.5% from RMB 264.5 million in 2024 to RMB 218.0 million in 2025, primarily due to reduced share-based compensation expenses[47]. - The net financial cost rose by 25.1% from RMB 8.0 million in 2024 to RMB 10.0 million in 2025, influenced by decreased bank deposit interest income[53]. - The company incurred research and development expenses of RMB 3,996 thousand, indicating a commitment to innovation[85]. - Financial costs decreased to RMB 10,034 thousand from RMB 8,023 thousand, reflecting better financial management[85]. Risks and Challenges - Key risks include changes in healthcare regulations, patient safety incidents, talent retention, and market acceptance of new health subscription services[38]. - The company is strategically exiting medical insurance services at the Wuhan Beidouxing Children's Hospital, which is expected to impact revenue in the short term[41]. Governance and Corporate Structure - The board of directors includes both executive and non-executive members, ensuring diverse governance[135]. - The company has a membership program launched in December 2020, providing various benefits to members, which may contribute to future revenue growth[131]. - The company completed its listing on the Hong Kong Stock Exchange on February 6, 2026, which may enhance its market presence and capital access[128].

Financial Performance - Total revenue for the year ended December 31, 2025, was RMB 1,545,598, a decrease of 6.8% compared to RMB 1,657,727 in 2024[5] - Gross profit for the same period was RMB 785,503, down 14.5% from RMB 918,629 in 2024, resulting in a gross margin of 50.8%[5] - Net profit for 2025 was RMB 347,787, reflecting a decline of 19.2% from RMB 430,677 in 2024, with a net profit margin of 22.5%[5] - Revenue from virtual goods sales was approximately RMB 1.5 billion, down 6.1% from approximately RMB 1.6 billion in the previous year[22] - The company's gross profit decreased from approximately RMB 918.6 million in 2024 to approximately RMB 785.5 million in 2025, with a gross margin decline from 55.4% to 50.8%[24] - The net profit for the fiscal year ending December 31, 2025, was approximately RMB 347.8 million, a decrease of about 19.2% from RMB 430.7 million in 2024[33] - Adjusted net profit, excluding share-based compensation, was approximately RMB 387.0 million, down 15.2% from approximately RMB 456.2 million in the previous year[34] - The company reported a basic earnings per share of RMB 0.343, down from RMB 0.427 in 2024, reflecting a decline of 19.67%[78] User Engagement - Monthly active users decreased to 19,927 in 2025 from 23,636 in 2024, while daily active users fell to 3,701 from 4,316[13] - The average revenue per paying user (ARPPU) for virtual items increased to RMB 272 in 2025 from RMB 256 in 2024[13] - The revenue from casual games increased significantly by 127.8% to RMB 241.1 million, driven by the success of the game "Fishing Master"[21] Operational Strategies - The company launched new gameplay features for its flagship product "Finger Sichuan Mahjong," enhancing user engagement and product longevity[8] - The company is focusing on AI integration across its operations, establishing an AI architecture to enhance game development and user experience[9][10] - Future strategies include optimizing user experience through long-term operations and enhancing AI capabilities to drive efficiency upgrades[14][15] - The company aims to deepen its domestic market presence while building a matrix of high-quality games, particularly in the casual gaming segment[16] - The company is focusing on exploring overseas markets and increasing investment in product development and art optimization[18] Expenses and Investments - Sales and distribution expenses increased by 14.3% to approximately RMB 169.2 million, primarily due to increased advertising and promotional expenses[27] - Research and development expenses rose by 5.0% to approximately RMB 132.9 million, mainly due to an increase in share-based payments[29] - The capital expenditure for the year ended December 31, 2025, was approximately RMB 11.4 million, primarily for investments, office renovations, and the purchase of fixed assets[37] Cash Flow and Assets - The group's total cash and cash equivalents decreased from approximately RMB 1.8 billion as of December 31, 2024, to approximately RMB 1.5 billion as of December 31, 2025[35] - The total assets less current liabilities amounted to RMB 2,632.3 million as of December 31, 2025, compared to RMB 2,612.2 million as of December 31, 2024[46] - Cash and cash equivalents decreased to RMB 60,035,000 in 2025 from RMB 425,665,000 in 2024, a decline of approximately 85.9%[85] Tax and Liabilities - The company reported a significant decrease in income tax expenses, from approximately RMB 181.4 million in 2024 to approximately RMB 98.2 million in 2025, a reduction of RMB 83.2 million[32] - The group reported a capital debt ratio of 0.01% as of December 31, 2025, compared to 0% as of December 31, 2024[36] - The group had no significant contingent liabilities as of December 31, 2025[38] Shareholder Information - The company plans to distribute an interim dividend of HKD 0.20 per share, compared to no dividend in 2024[76] - The proposed final dividend for the fiscal year ending December 31, 2025, is HKD 0.20 per share, up from HKD 0.15 per share in 2024, totaling approximately HKD 207 million[92] - The company plans to maintain a dividend payout of no less than 30% of the group's profit for the relevant fiscal year[94] - The total issued shares increased from 1,032,338,937 in 2024 to 1,034,975,187 in 2025, an increase of 0.16%[89] Compliance and Governance - The financial statements are prepared in accordance with the Hong Kong Financial Reporting Standards and presented in Renminbi (RMB) adjusted to the nearest thousand (RMB thousand) [49] - The consolidated financial statements include the financial statements of the company and its subsidiaries for the year ending December 31, 2025 [50] - The audit committee confirmed compliance with applicable accounting principles and standards for the fiscal year ending December 31, 2025[99] - The company has adopted an updated dividend policy to allow for the declaration and payment of dividends while retaining sufficient reserves for future growth[93] Market and Operational Risks - The group faced foreign exchange risks due to holding cash and bank balances in USD and HKD, with no current foreign currency hedging policy in place[42] - The company operates under a free-to-play model, allowing players to play games for free while offering in-game purchases[105] - The company has not engaged in any buying or redeeming of its listed securities as of December 31, 2025[102]

Financial Performance - For the year ending December 31, 2025, the group's revenue was approximately HKD 92.1 million, an increase of about HKD 10.6 million or 13.0% compared to HKD 81.5 million for the year ending December 31, 2024[4] - The loss for the year ending December 31, 2025, was approximately HKD 16.8 million, compared to a loss of about HKD 5.5 million for the year ending December 31, 2024[4] - Basic loss per share for the year ending December 31, 2025, was approximately HKD 5.83, compared to about HKD 1.90 for the year ending December 31, 2024[4] - The company reported a pre-tax loss of HKD 16,156,000 for the fiscal year 2025, compared to a pre-tax loss of HKD 5,007,000 in 2024, indicating a significant increase in losses[17] - The group recorded a net loss of approximately HKD 16.8 million for the year ended December 31, 2025, compared to a loss of approximately HKD 5.5 million for the year ended December 31, 2024, primarily due to rising administrative expenses[41] Revenue and Sales - For the fiscal year ending December 31, 2025, total external sales amounted to HKD 92,106,000, an increase from HKD 81,546,000 in the previous year, representing a growth of approximately 12.8%[17] - Revenue from customers in China reached HKD 76,298,000 in 2025, up from HKD 68,858,000 in 2024, reflecting a growth of approximately 10.5%[18] - Major customer A contributed HKD 14,845,000 to revenue in 2025, an increase from HKD 12,164,000 in 2024, while major customer B was not applicable in 2025 but contributed HKD 9,445,000 in 2024[19] - Revenue from the sale of industrial aluminum electrolytic capacitors increased from approximately HKD 68.7 million in 2024 to approximately HKD 78.8 million in 2025, a growth of about HKD 10.1 million[33] Profitability and Margins - The gross profit margin decreased from approximately 7.5% for the year ending December 31, 2024, to about 7.2% for the year ending December 31, 2025[4] - The group's gross profit increased from approximately HKD 6.1 million for the year ended December 31, 2024, to approximately HKD 6.7 million for the year ended December 31, 2025, while the gross margin decreased from about 7.5% to 7.2% due to rising raw material costs and competitive pricing strategies[35] - Gross profit margin slightly decreased from 7.5% to 7.2%, a decline of 0.3 percentage points, primarily due to rising raw material costs and competitive pricing strategies[31] Assets and Liabilities - Non-current assets decreased from HKD 29.0 million in 2024 to HKD 24.9 million in 2025[6] - Current assets decreased from HKD 67.6 million in 2024 to HKD 63.2 million in 2025[6] - Current liabilities increased from HKD 26.6 million in 2024 to HKD 32.4 million in 2025[6] - Total equity decreased from HKD 69.7 million in 2024 to HKD 55.0 million in 2025[6] - As of December 31, 2025, the group's total assets were approximately HKD 88.2 million, down from HKD 96.6 million in 2024, with total liabilities and equity at approximately HKD 33.1 million and HKD 55.0 million, respectively[43] Dividends and Shareholder Returns - The board of directors did not recommend the payment of a final dividend for the year ending December 31, 2025, consistent with the previous year[4] - The company did not declare or recommend any dividends for the year 2025, consistent with 2024[25] Corporate Governance and Compliance - The company adhered to the corporate governance code, with a noted deviation from the principle that the roles of chairman and CEO should be separated[59] - The company appointed a new chairman and CEO, Mr. Mai Junhui, on February 27, 2025, to enhance operational efficiency[60] - The company has implemented measures to ensure compliance with securities trading regulations among its directors and employees[64] - At least 25% of the company's issued shares were held by the public as of December 31, 2025, in compliance with GEM listing rules[65] - The audit committee, consisting of three independent non-executive directors, has been established to oversee internal audit functions and financial reporting[68] Strategic Initiatives - The company is primarily engaged in the manufacturing and trading of aluminum electrolytic capacitors and electronic components, with a new subsidiary established in Dubai to provide SaaS and digital marketing solutions[7] - The company successfully completed a placement on January 21, 2026, raising key funds to develop its Dubai subsidiary's SaaS and marketing solutions business[32] - A distribution agreement worth USD 3 million was signed with a Macau distributor for the SaaS and marketing solutions business, expected to enhance market positioning and future growth[32] - The group established a wholly-owned subsidiary in China to support its SaaS solutions and digital product business operations and sales activities[47] - The group entered into a contract with an independent third-party distributor in Macau for a total value of approximately USD 3 million related to SaaS annual licensing and related services[47] Expenses and Other Income - Administrative expenses increased from approximately HKD 13.5 million for the year ended December 31, 2024, to approximately HKD 18.9 million for the year ended December 31, 2025, driven by higher professional service fees and increased employee costs[39] - Other income decreased from approximately HKD 2.4 million for the year ended December 31, 2024, to approximately HKD 1.5 million for the year ended December 31, 2025, primarily due to a reduction in fee income[36] - Net other gains and losses dropped from a gain of approximately HKD 3.6 million for the year ended December 31, 2024, to a loss of approximately HKD 1.7 million for the year ended December 31, 2025, mainly due to a decline in fair value gains from equity investments[37] Accounting Standards - The company has not applied any new or revised Hong Kong Financial Reporting Standards that are not yet effective, indicating a conservative approach to accounting changes[10] - The company expects that the application of new accounting standards will not have a significant impact on the consolidated financial statements in the foreseeable future[11] - The company is currently assessing the specific impact of the new Hong Kong Financial Reporting Standard No. 18 on its consolidated financial statements[12] - The segment performance metrics are reported to the chief operating decision maker for resource allocation and performance evaluation purposes[16]

Financial Performance - For the fiscal year ending December 31, 2025, the group reported total contract sales of approximately RMB 90.93 billion, a decrease of about RMB 12.43 billion or 12.0% compared to the previous fiscal year[2]. - The total revenue for the fiscal year was approximately RMB 136.79 billion, representing a decrease of about RMB 6.20 billion or 4.3% year-on-year[2]. - The profit attributable to equity holders was approximately RMB 3.65 billion, down by RMB 1.15 billion or 24.0% compared to the previous fiscal year[2]. - The basic earnings per share for the fiscal year was RMB 1.58[2]. - The group recorded a net profit of approximately RMB 5.54 billion for the fiscal year, down from RMB 6.39 billion in the previous year[4]. - The group’s revenue from property development was approximately RMB 132.36 billion, a decrease of about RMB 6.26 billion or 4.5% year-on-year[2]. - The group’s total comprehensive income for the year was approximately RMB 5.61 billion, compared to RMB 6.35 billion in the previous year[5]. - The total gross profit for the fiscal year was approximately RMB 19.01 billion, compared to RMB 18.97 billion in the previous year[4]. Assets and Liabilities - Total assets increased from RMB 368,248,213 thousand to RMB 412,483,385 thousand, representing a growth of approximately 12%[7]. - Total liabilities rose from RMB 272,098,920 thousand to RMB 309,978,492 thousand, indicating an increase of about 14%[9]. - Net value of current assets decreased from RMB 146,240,583 thousand to RMB 130,076,014 thousand, a decline of approximately 11%[9]. - The company's equity attributable to owners increased from RMB 30,096,850 thousand to RMB 25,559,870 thousand, reflecting a decrease of around 15%[9]. - The company’s total liabilities to total assets ratio increased from 73.8% to 75.1%, indicating a higher leverage position[9]. Cash Flow and Dividends - The group achieved cash collections from property development of approximately RMB 127.53 billion for the fiscal year[2]. - The board proposed a final dividend of HKD 0.9 per share, down from HKD 1.2 per share in the previous year[2]. - The proposed final dividend per share for 2025 is HKD 0.9, down from HKD 1.2 in 2024, reflecting a decrease of 25%[33]. - The total proposed final dividend amount for 2025 is approximately RMB 1,821,017,000, compared to RMB 2,241,585,000 in 2024, a decrease of about 18.7%[33]. Financial Reporting Standards - The financial statements were prepared in accordance with all applicable Hong Kong Financial Reporting Standards and comply with the disclosure requirements of the Hong Kong Companies Ordinance and the Listing Rules[13]. - Significant accounting policies have been consistently applied across all reporting periods, with new or revised Hong Kong Financial Reporting Standards disclosed in Note 3[14]. - The Group adopted the revised Hong Kong Financial Reporting Standard No. 21, effective from January 1, 2025, which addresses the issue of lack of exchangeability[15]. - The revised standard is not expected to have a significant impact on the Group's financial statements[16]. - The new Hong Kong Financial Reporting Standards (HKFRS) will take effect from January 1, 2027, impacting the group's financial reporting policies[21]. Market and Sales Performance - The competitive landscape in the real estate industry has adjusted significantly, with market resources concentrating on financially stable and strategically positioned companies[48]. - The "Good Housing" policy has shifted customer demand from merely having housing to a focus on quality housing, leading to higher expectations for property quality and services[47]. - The company is focusing on market expansion strategies to recover from the sales decline experienced in the past fiscal year[53]. - New product developments and technological advancements are being prioritized to enhance competitive positioning in the market[53]. - Future performance guidance indicates a cautious outlook, with expectations of gradual recovery in sales as market conditions improve[53]. Employee and Operational Management - As of December 31, 2025, the group employed a total of 23,153 full-time employees, with total employee costs approximately RMB 4.05 billion, a decrease from RMB 4.28 billion in the previous year[81]. - The company is committed to maintaining high corporate governance standards to enhance shareholder value and transparency[98]. - The company plans to optimize existing assets and enhance core competitiveness while focusing on precise land acquisition strategies to increase market share[87]. Other Financial Metrics - The company reported a provision for expected credit losses of RMB 77,864,000 for loans to joint ventures and associates, an increase from RMB 56,256,000 in the previous year[26]. - The depreciation expense for owned assets increased to RMB 56,591,000 in 2025 from RMB 44,571,000 in 2024, marking a rise of approximately 27%[26]. - The company recorded a foreign exchange loss of RMB 9,671,000 in 2025, compared to a gain of RMB 9,687,000 in 2024[26]. - The total amount of land value-added tax for 2025 was RMB 391,440,000, significantly lower than RMB 1,006,174,000 in 2024, indicating a decrease of about 61%[27].

Financial Performance - Total revenue for the year ended December 31, 2025, was RMB 124,561,000, a decrease of 17.3% from RMB 150,546,000 in 2024[2] - Gross profit for the same period was RMB 14,666,000, down from RMB 15,637,000, reflecting a gross margin of approximately 11.8%[2] - Operating loss for the year was RMB 63,340,000, slightly improved from a loss of RMB 69,131,000 in 2024[2] - Net loss attributable to owners of the company was RMB 66,547,000, compared to RMB 70,833,000 in the previous year, indicating a reduction of 6.4%[3] - Basic and diluted loss per share for the year was RMB 0.21, compared to RMB 0.23 in 2024[3] Assets and Liabilities - Total assets decreased to RMB 193,007,000 from RMB 247,932,000, a decline of 22.2%[4] - Non-current assets totaled RMB 45,361,000, down from RMB 58,396,000, a decrease of 22.3%[4] - Total liabilities slightly decreased to RMB 56,060,000 in 2025 from RMB 57,478,000 in 2024, a decline of 2.5%[14] - The group's total assets decreased to RMB 238,368,000 in 2025 from RMB 306,328,000 in 2024, reflecting a decline of 22.2%[14] Revenue Sources - Major customer A contributed RMB 64,038,000 to the total revenue in 2025, down from RMB 82,599,000 in 2024, a decline of 22.6%[17] - The group’s revenue from the Chinese market accounted for the majority of its total revenue, with RMB 124,157,000 generated in 2025[19] Expenses - Research and development expenses increased to RMB 20,241,000 from RMB 16,106,000, representing a rise of 25.5%[2] - The company's sales and service costs for the year ending December 31, 2025, were RMB 99,017,000, a decrease of 19.3% from RMB 122,666,000 in 2024[23] - The total employee costs, including director remuneration, amounted to RMB 86,536,000 in 2025, down from RMB 92,059,000 in 2024, reflecting a reduction of 6.5%[23] - Administrative expenses decreased by approximately RMB 8,200,000 or 23.1% to about RMB 27,300,000, attributed to strict cost control measures[50] Cash Flow and Investments - Cash and cash equivalents at year-end were RMB 148,009,000, significantly lower than RMB 201,806,000 in 2024[4] - The company incurred capital expenditures of approximately RMB 773,000 for leasing property renovations and equipment in 2025, compared to RMB 297,000 in 2024, indicating a significant increase[33] Market and Strategic Initiatives - The group continues to enhance its cloud intelligence and data intelligence product offerings, focusing on integrating AI technologies into various industry applications[41] - The establishment of the Futong AI Innovation Center aims to improve AI product development and technical service capabilities, supported by a research team from renowned universities[64] - The group is actively expanding into overseas markets and enhancing cooperation with international partners to provide AI-enabled services for businesses looking to expand abroad[65] - The group aims to enhance its development in digital products and cloud intelligence products, focusing on AI, cloud computing, and big data technologies[63] Governance and Future Outlook - The board does not recommend the payment of a final dividend for the year ending December 31, 2025[57] - The annual general meeting is scheduled for May 21, 2026, with a suspension of share transfer registration from May 18 to May 21, 2026[58][59] - The group will continue to implement refined resource management and strict cost control measures to maintain a stable financial position amid global economic fluctuations[65] - The overall revenue of the group slightly declined due to intense market competition, with expectations for moderate economic growth in China for 2026[63] Employee Information - As of December 31, 2025, the group had 247 employees in China and Hong Kong, with total employee costs amounting to approximately RMB 86.5 million, a decrease from RMB 92.1 million in 2024[60] Other Financial Metrics - Interest income fell significantly to RMB 3,340,000 in 2025 from RMB 10,466,000 in 2024, a decrease of 68.1%[21] - The group reported a loss before tax of RMB 63,441,000 for 2025, compared to a loss of RMB 69,272,000 in 2024, indicating an improvement of 8.5%[12] - The provision for trade receivables loss at the end of 2025 was RMB 9,821,000, up from RMB 8,633,000 in 2024, marking an increase of 13.8%[37] - The total amount of trade payables increased to RMB 14,620,000 in 2025 from RMB 11,173,000 in 2024, reflecting a rise of 31.0%[38] - The deferred tax expense for the year ending December 31, 2025, was RMB 3,148,000, compared to RMB 1,596,000 in 2024, showing an increase of 97.5%[26]

Financial Performance - The group's revenue for the year ended December 31, 2025, was approximately RMB 3,880.5 million, an increase of about 17.8% compared to RMB 3,292.9 million for the year ended December 31, 2024[2]. - The group's gross profit for the year was approximately RMB 823.2 million, up about 16.5% from RMB 706.7 million in the previous year, with a gross profit margin of approximately 21.2%, a decrease of 0.3 percentage points from 21.5%[2]. - The group's net profit for the year was approximately RMB 373.8 million, an increase of about 14.0% from RMB 327.9 million in the previous year, with profit attributable to equity holders of the company at approximately RMB 358.9 million, up about 11.0% from RMB 323.5 million[2]. - The company reported a total revenue of RMB 799,910,000 in 2025, compared to RMB 662,696,000 in 2024, reflecting a growth of approximately 20.7%[5]. - Profit before tax increased to approximately RMB 497.9 million, up about 18.3% from RMB 420.8 million for the year ended December 31, 2024[73]. - The company's profit attributable to equity holders for the year was approximately RMB 358.9 million, an increase of about 11.0% compared to RMB 323.5 million for the year ended December 31, 2024[75]. Assets and Liabilities - Total assets as of December 31, 2025, amounted to RMB 4,315,348,000, an increase from RMB 3,685,838,000 in 2024, representing a growth of approximately 17.1%[5]. - Current liabilities increased to RMB 2,403,458,000 in 2025 from RMB 2,020,287,000 in 2024, reflecting a rise of about 19.0%[5]. - The net asset value of the company reached RMB 2,057,855,000 in 2025, up from RMB 1,810,610,000 in 2024, indicating an increase of approximately 13.6%[6]. - The company's total liabilities decreased to RMB 2,257,493,000 in 2025 from RMB 2,020,287,000 in 2024, showing a reduction of approximately 11.7%[6]. - The company's equity attributable to owners increased to RMB 2,006,742,000 in 2025 from RMB 1,762,216,000 in 2024, representing a growth of about 13.9%[6]. - The company's non-current liabilities decreased to RMB 107,696,000 in 2025 from RMB 44,044,000 in 2024, indicating a decrease of approximately 11.5%[6]. Revenue Sources - Revenue from property management services was RMB 1,781,077 thousand for the fiscal year ending December 31, 2024, and is projected to increase to RMB 2,225,351 thousand for the fiscal year ending December 31, 2025[19]. - Revenue from commercial property operation management services increased from RMB 80,915 thousand in 2024 to RMB 102,263 thousand in 2025[19]. - Property management services remain the largest revenue source, generating approximately RMB 2,225.4 million, accounting for about 57.3% of total revenue[63]. - Revenue from community value-added and collaborative services increased from approximately RMB 760.3 million to about RMB 937.3 million, representing a growth of approximately 23.3%[64]. - Revenue from non-core value-added services decreased from approximately RMB 670.6 million to about RMB 615.7 million, a decline of about 8.2%[64]. - Revenue from commercial property management services increased by approximately 26.4% to about RMB 102.3 million, driven by projects entering the preparation and operational phases[65]. Dividends - The board proposed a final dividend of HKD 0.15 per share and a special dividend of HKD 0.05 per share, maintaining the final dividend from the previous year[2]. - The proposed final dividend for 2025 is HKD 0.15 per share and a special dividend of HKD 0.05 per share, totaling approximately HKD 281,653,000 (approximately RMB 254,394,000)[40]. Operational Highlights - The total contracted gross floor area for property management services was approximately 117.3 million square meters as of December 31, 2025, representing a growth of about 7.5% from 109.1 million square meters as of December 31, 2024[2]. - The company serves over 538,000 households as of December 31, 2025, with a total contracted building area of approximately 117.3 million square meters[43]. - The company ranked 13th in the "Top 100 Property Service Enterprises in China" for 2025, improving by 3 positions from 2024[42]. - The company operates in 66 cities across 16 provinces, municipalities, and autonomous regions in China, including major cities like Beijing and Shanghai[42]. - The company has four main business lines: property management services, community value-added services, non-owner value-added services, and commercial property operation management services[43]. Taxation - The income tax expense for 2025 was RMB 124,155 thousand, compared to RMB 92,937 thousand in 2024, reflecting a significant increase of 33.5%[31]. - The current income tax for corporate income tax in China was RMB 126,028 thousand in 2025, up from RMB 106,045 thousand in 2024, marking an increase of 18.9%[31]. - The effective corporate income tax rate for the group in China is 25%, with a preferential rate of 20% applicable to qualifying small and micro enterprises[34]. Employee and Governance - The company employed 17,506 employees as of December 31, 2025, an increase from 15,835 employees as of December 31, 2024[93]. - The company maintains high standards of corporate governance to protect shareholder interests and enhance corporate value[103]. - The audit committee has reviewed the group's consolidated financial statements for the year[106]. Future Outlook - The company plans to selectively invest in or acquire other property management companies when suitable opportunities arise, although there are uncertainties and risks associated with such acquisitions[86]. - The company aims to enhance service experience and operational efficiency through AI-driven tools and improved customer complaint management[95]. - The company plans to expand its business scale by strengthening risk control and exploring acquisition opportunities to enhance market concentration[96].

Financial Performance - For the fourth quarter of 2025, the company achieved a revenue of RMB 750.7 million, representing a year-on-year increase of 46.1% and a quarter-on-quarter increase of 84.4%[11]. - The company recorded a net profit of RMB 103.7 million in the fourth quarter of 2025, compared to a net loss of RMB 131.1 million in the same quarter of 2024, marking the first profitable quarter since its establishment[5]. - The company’s annual net loss was significantly reduced from RMB 481.8 million in 2024 to RMB 145.0 million in 2025[5]. - Total revenue for 2025 reached RMB 1,941.0 million, representing a year-on-year growth of 17.7%; total sales of LiDAR units were approximately 912,000, an increase of 67.6% year-on-year[16]. - Net loss for 2025 narrowed to RMB 145.0 million, with adjusted net loss under non-IFRS further reduced to RMB 53.5 million[16]. - The company achieved an annual production capacity layout of 4 million units, ensuring scalability for ADAS and robotics business demands in 2026[25]. - Operating loss decreased significantly from RMB 584.2 million in 2024 to RMB 184.3 million in 2025, indicating improved operational efficiency[27]. - The company reported a net loss of RMB 144,966 thousand for 2025, a reduction from a net loss of RMB 481,805 thousand in 2024, showing improved financial performance[74]. - The basic loss per share for the year ended December 31, 2025, was RMB (0.32), an improvement from RMB (1.11) in 2024, reflecting a reduction in losses[108]. Revenue Breakdown - The total sales volume of LiDAR products reached approximately 459,600 units in the fourth quarter of 2025, a significant year-on-year increase of 183.2%[5]. - The sales revenue from robotics and other products surged to RMB 346.7 million in the fourth quarter of 2025, reflecting a year-on-year growth of 427.5%[10]. - Revenue from products used in ADAS applications decreased by approximately 17.2% to RMB 1,105.9 million in 2025, despite a sales volume increase of 17.2% to approximately 609,000 units[28]. - Revenue from robotics and other products surged by approximately 257.7% to RMB 709.8 million in 2025, with total sales volume increasing by 1,141.8% to approximately 303,000 units[28]. - Revenue from sales solutions decreased by approximately 20.8% from RMB 98.0 million in 2024 to RMB 77.6 million in 2025, despite an increase in average project price from approximately RMB 296,000 to RMB 792,200[32]. - Revenue from services and others increased by approximately 177.0% from RMB 17.2 million in 2024 to RMB 47.6 million in 2025, driven by an increase in completed technical service projects[32]. Gross Profit and Margins - The gross profit margin for the fourth quarter of 2025 improved to 28.5%, an increase of 6.4 percentage points year-on-year[11]. - Comprehensive gross margin for 2025 improved to 26.5%, up 9.3 percentage points from 2024, with gross profit increasing by 81.3% year-on-year[16]. - Overall gross margin increased due to improved margins for LiDAR products used in ADAS applications, rising from 13.4% in 2024 to 19.1% in 2025, an increase of approximately 5.7 percentage points[31]. - Gross profit for LiDAR products used in ADAS applications increased by approximately 17.7% from RMB 179.2 million in 2024 to RMB 210.9 million in 2025[31]. - Gross profit increased by approximately 87.7% from RMB 113.8 million in Q4 2024 to RMB 213.6 million in Q4 2025, with gross margin improving from 22.1% to 28.5%[49]. Research and Development - Research and development expenses rose to RMB 646.7 million in 2025, up from RMB 615.4 million in 2024, highlighting continued investment in innovation[27]. - R&D expenses increased by approximately 5.1% from RMB 615.4 million in 2024 to RMB 646.7 million in 2025, with R&D expenses as a percentage of revenue decreasing from 33.6% to 29.9%[34]. - R&D expenses rose by 5.2% from RMB 150.3 million in Q4 2024 to RMB 158.2 million in Q4 2025, while the percentage of R&D expenses to revenue decreased from 28.7% to 19.0%[53]. Partnerships and Market Position - The company established partnerships for mass production of LiDAR products with 163 vehicle models as of December 31, 2025, including 33 partnerships with overseas manufacturers[7]. - The company secured over 90% of core Robotaxi and Robotruck players as partners, significantly increasing market share from approximately 10% to over 90% in the digital era[19]. - In the ADAS sector, the company has secured 163 model designations from 34 automotive manufacturers and tier-one suppliers[23]. - The company achieved the title of top seller in the 3D LiDAR market for robots in China, with significant growth in various segments including lawnmowers and commercial cleaning robots[24]. Assets and Liabilities - Total assets increased to RMB 5,265.7 million in 2025 from RMB 4,139.1 million in 2024, reflecting strong growth in both current and non-current assets[27]. - Total liabilities increased to RMB 1,460,243 thousand from RMB 1,065,959 thousand, indicating a rise in financial obligations[77]. - Trade receivables increased to RMB 616,919,000 in 2025 from RMB 410,611,000 in 2024, with net trade receivables at RMB 597,299,000 after accounting for credit loss provisions[110]. - Cash and cash equivalents decreased to RMB 2,097,873,000 in 2025 from RMB 2,835,984,000 in 2024, with a notable decline in time deposits[111]. Corporate Governance and Compliance - The company was officially listed on the Hong Kong Stock Exchange on January 5, 2024[80]. - The company has adopted a post-IPO share incentive plan approved by shareholders, effective from June 29, 2023[129]. - The audit committee, consisting of non-executive directors, has reviewed the consolidated financial statements during the reporting period[125]. - The company emphasizes that the financial data presented is unaudited and may change, urging shareholders and potential investors to act cautiously[131]. Future Outlook - The company plans to maintain a balanced revenue contribution from both ADAS and robotics businesses moving forward[25]. - The company is transitioning products from development and testing to mass production, indicating readiness for commercialization[133].